Drug Profile


Alternative Names: 430C78; BW 430C; Labileno; Lamactil; Lamictal; Lamictin

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator GlaxoSmithKline
  • Class Antiepileptic drugs; Small molecules; Triazines
  • Mechanism of Action Sodium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Bipolar disorders; Lennox-Gastaut syndrome; Partial epilepsies; Tonic-clonic epilepsy
  • Phase III Absence epilepsy; Epilepsy
  • Discontinued Diabetic neuropathies; Neuropathic pain; Schizophrenia

Most Recent Events

  • 16 May 2017 GlaxoSmithKline terminates a clinical trial in Bipolar disorders (Adjunctive treatment, In adolescents) in USA (NCT00284791)
  • 14 Jun 2016 Biomarkers information updated
  • 01 Nov 2015 GlaxoSmithKline completes a phase III trial in Absence epilepsy (In adolescents, In children, Monotherapy, Newly diagnosed) in Japan and South Korea (NCT01431976)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top